Replies to post #885 on ANI Pharmaceuticals (ANIP)

[RallyTheMarket]

Oh man, we just skipped right over $40-50 and $50-$60. Straight to $70. I've liked how for the last 2-3 years now the story continues to be that BPAX/ANIP isn't treated fairly. Pharmaceutical companies get bought up all the time by big companies who aren't afraid to pull out their wallets, but for some reason when it comes to BPAX/ANIP there's some "game" being played. Because, you know, when there's "billions" to be made all these companies are willing to lose out so they can save a few cents on the PPS. I don't think so.

[Textbook_Hippie_Man]

How about we just try to hold $12, ok? Damn grand notions on this board. We're not even close to $70. 5 years easy, if ever, before we get to pre-Libi disaster prices. $70? Come on.

[Just the facts maam]

According to the ANI Q2 earning release

The net loss was $4.6 million for the three months ended June 30, 2013, which included $5.5 million of merger-related expenses.

This equates to $0.9 million in net income, an EPS of approx. $0.09, when you exclude the merger related expenses. If it were trading at quarterly earning multiples of 164 which was the average of the group ANI used for business comparisons. Today's PPS should be approx. $15.46.

Looks like that will only grow on November 7th, as merger related expenses should have been concluded in Q2.